

1 **Country wide surveillance reveals prevalent artemisinin partial resistance mutations with**
2 **evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine**
3 **resistance mutations in northwest Tanzania.**

4
5 Jonathan J. Juliano¹⁺, David J. Giesbrecht²⁺, Alfred Simkin², Abebe A. Fola², Beatus M.
6 Lyimo^{3,4}, Dativa Pereus³, Catherine Bakari³, Rashid A. Madebe³, Misago D. Seth³, Celine I.
7 Mandara³, Zachary R. Popkin-Hall¹, Ramadhan Moshi³, Ruth B. Mbwambo³, Karamoko Niaré²,
8 Bronwyn MacInnis^{5,6}, Filbert Francis², Daniel Mbwambo⁷, Issa Garimo⁷, Frank Chacky⁷,
9 Sijenunu Aaron⁷, Abdallah Lusasi⁷, Fabrizio Molteni⁸, Ritha J. A. Njau⁹, Samwel Lazaro⁷, Ally
10 Mohamed⁷, Jeffrey A. Bailey^{2,*}, Deus S. Ishengoma^{3,5,10*#}

11
12
13 ¹University of North Carolina, Chapel Hill, NC, USA

14 ²Brown University, Providence, RI, USA

15 ³National Institute for Medical Research, Dar es Salaam, Tanzania.

16 ⁴Nelson Mandela African Institute of Science and Technology, Arusha, Tanzania

17 ⁵Harvard T.H Chan School of Public Health, Boston, MA, USA

18 ⁶Broad Institute, Boston, MA, USA.

19 ⁷National Malaria Control Programme, Dodoma, Tanzania

20 ⁸Swiss Tropical Public Health Institute, Dar es Salaam, Tanzania

21 ⁹Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

22 ¹⁰Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia

23
24 +: co-first author

25 *: co-senior authors

26
27 #Corresponding author: deusishe@yahoo.com
28

29 **Abstract**

30 **Background:** Emergence of artemisinin partial resistance (ART-R) in *Plasmodium falciparum* is
31 a growing threat to the efficacy of artemisinin combination therapies (ACT) and the efforts for
32 malaria elimination. The emergence of *Plasmodium falciparum* Kelch13 (K13) R561H in
33 Rwanda raised concern about the impact in neighboring Tanzania. In addition, regional concern
34 over resistance affecting sulfadoxine-pyrimethamine (SP), which is used for chemoprevention
35 strategies, is high.

36 **Methods:** To enhance longitudinal monitoring, the Molecular Surveillance of Malaria in
37 Tanzania (MSMT) project was launched in 2020 with the goal of assessing and mapping
38 antimalarial resistance. Community and clinic samples were assessed for resistance
39 polymorphisms using a molecular inversion probe platform.

40 **Findings:** Genotyping of 6,278 samples collected countrywide in 2021 revealed a focus of K13
41 561H mutants in northwestern Tanzania (Kagera) with prevalence of 7.7% (50/649). A small
42 number of 561H mutants (about 1%) were found as far as 800 km away in Tabora, Manyara, and
43 Njombe. Genomic analysis suggests some of these parasites are highly related to isolates
44 collected in Rwanda in 2015, supporting regional spread of 561H. However, a novel haplotype
45 was also observed, likely indicating a second origin in the region. Other validated resistance
46 polymorphisms (622I and 675V) were also identified. A focus of high sulfadoxine-
47 pyrimethamine drug resistance was also identified in Kagera with a prevalence of dihydrofolate
48 reductase 164L of 15% (80/526).

49 **Interpretation:** These findings demonstrate the K13 561H mutation is entrenched in the region
50 and that multiple origins of ART-R, similar as to what was seen in Southeast Asia, have
51 occurred. Mutations associated with high levels of SP resistance are increasing. These results
52 raise concerns about the long-term efficacy of artemisinin and chemoprevention antimalarials in
53 the region.

54 **Funding:** This study was funded by the Bill and Melinda Gates Foundation and the National
55 Institutes of Health.

56

57 **Research in Context**

58 **Evidence before this study**

59 We did a literature search via PubMed for research articles published from January 2014 to
60 October 2023 using the search term “Africa” and “Artemisinin resistance” linked to “R561H” or
61 “A675V” or “R622I”, returning 32 studies. The published literature shows the emergence and
62 establishment of these three validated *Plasmodium falciparum* kelch13 (K13) mutations
63 associated with artemisinin partial resistance (ART-R) in Africa. Large molecular studies of
64 675V in Uganda and 622I in Ethiopia have defined the regional spread of these mutations.
65 However, limited data is available from recent studies about the spread and origins of the 561H
66 mutation in the Great Lakes region of East Africa. In particular, detailed studies of the regions of
67 Tanzania that border Rwanda have not been carried out since the mutation was detected in
68 Rwanda. These data are needed for malaria control programs to define and implement strategies
69 for controlling the spread of ART-R in Africa, a potential global public health disaster and the
70 potential obstacle to the ongoing elimination strategies.

71 **Added value of this study**

72 This analysis reports the first large-scale analysis of antimalarial resistance in Tanzania, with a
73 focus on the regions bordering Rwanda since the 561H mutation reached high frequency in the
74 area. Using 6,278 *P. falciparum* positive samples sequenced using molecular inversion probes
75 (MIPs), we show that the mutation has become frequent in the districts of Kagera bordering
76 Rwanda. Importantly, we provide evidence for the separate emergence of a different extended
77 haplotype around 561H in Tanzania. This is the first evidence that multiple independent
78 emergences of the 561H ART-R have occurred in Africa, as was seen within the last two decades
79 in Southeast Asia.

80 **Implications of all the available evidence**

81 These findings highlight that, similar to 622I and 675V in other parts of Africa, we can expect
82 the 561H mutation to continue to spread in the region. In addition, it highlights that we need to
83 be watchful for new origins of mutations beyond the spread of existing resistant parasite
84 lineages. ART-R appears to now be well established in multiple areas in Eastern Africa.
85 Intensive control in these regions to prevent spread and monitoring for partner drug resistance

86 emergence in affected areas will be critical for preventing further reversal of malaria control
87 efforts in the region and support progress to the elimination targets by 2023.

88

89 INTRODUCTION

90 Resistance to drugs used for treatment and prevention of malaria poses one of the greatest threats
91 to global control and is of grave concern in Africa where the vast majority of cases and deaths
92 occur.¹ Historically, the emergence and spread of chloroquine and sulfadoxine-pyrimethamine
93 (SP) resistance resulted in the collapse of effective treatment of malaria with significant
94 increases in morbidity and mortality.² Antimalarial combination therapies, consisting of an
95 artemisinin derivative and a partner drug (artemisinin-based combination therapy - ACTs), are
96 currently the predominant therapeutic options for treating uncomplicated falciparum malaria.
97 Given gains in malaria control have already plateaued and are reversing in some countries, the
98 emergence of artemisinin partial resistance (ART-R) in Africa could be a global public health
99 disaster if partner drug resistance emerges in concert resulting in frank ACT failure.³

100

101 Over a decade has passed since the emergence of ART-R in SouthEast Asian *P. falciparum*
102 populations, leading to decreased drug efficacy.⁴ Clinical ART-R was first demonstrated in the
103 late 2000s in studies conducted in Western Cambodia. The emergence of ART-R in Western
104 Cambodia set the stage for the eventual failure of ACTs, as resistance to the partner drugs also
105 emerged, indicated by increasing treatment failures, parasite clearance times and partner drug
106 IC50s over a very short timeframe.³ Early in the emergence of ACT resistance, many areas of
107 SEA experienced more than 50% failure in patients treated with ACTs due to the combined
108 effect of artemisinin and partner drug resistance.³

109

110 Mutations in *Plasmodium falciparum* Kelch13 (K13) (PF3D7_1343700) are the key mediator of
111 ART-R. These mutations were originally identified through drug pressure experiments and
112 validated in the field and by genetic engineering studies.⁵ They are thought to alter ubiquitination
113 patterns and help parasites to resist accumulation of polyubiquitinated proteins.⁵ A number of
114 key mutations in K13 propeller domain are now validated markers of ART-R. Unfortunately,
115 validated K13 mutations have now been found extensively in Eastern Africa, particularly in the
116 Horn of Africa (R622I), Uganda (C469Y, A675V), Rwanda (R561H), and Tanzania (R561H).⁶⁻

117 ¹⁰

118

119 The regional emergence and spread of these mutations appears to be developing as the norm
120 rather than the exception. In the Horn of Africa, the validated 622I mutation was first reported in
121 2014.¹¹ Since that time, these mutations have spread across Eritrea and Ethiopia.^{7,8} In Uganda,
122 longitudinal molecular surveillance at 16 sites has painted a clear picture of spread within
123 Uganda of the 469Y and 675V variants.⁶ It is important to note that all three of these mutations
124 have been associated with prolonged parasite clearance, day 3 positivity by microscopy,
125 increasing prevalence over time, and are in regions that now meet WHO criteria for ART-R.^{7,8}

126

127 The emergence and spread of the 561H mutation in the Great Lakes Region of East Africa is not
128 yet as clear when compared to other mutations. Originally described in Rwanda in samples from
129 2014 and 2015, this mutation appears to have emerged within the country over the past
130 decade.^{10,12} In 2015, 7.4% of samples collected in Masaka harbored the 561H mutation.¹⁰ By
131 2018, 561H prevalence had increased to 19.6% in Masaka and 22% in Rukara during a
132 therapeutic efficacy study.¹³ In this study, 50% of isolates with delayed clearance (day 3 positive
133 parasitemia) carried 561H. On this basis, Masaka met the WHO criteria for endemic ART-R as
134 defined by >5% of patients carrying K13 resistance-confirmed mutation for which they had
135 persistent parasitemia by microscopy on day 3.¹⁴ Genome sequencing of isolates from 2015 also
136 confirmed a single haplotype of 561H in Rwanda that was not of Asian origin, suggesting *de*
137 *novo* mutation within Africa.¹⁰

138

139 Importantly, K13 mutations should never be studied in isolation as it requires partner drug
140 resistance to lead to clinical failures of ACTs. Further, mutations to drugs no longer used for
141 therapy, but that remain in use for chemoprevention (e.g. SP), are also important to characterize
142 for malaria control programs. Molecular surveillance of antimalarial resistance should therefore
143 rely on platforms that can broadly detect different resistance mutations. Highly multiplex
144 amplicon deep sequencing is one approach that has shown promise. Another approach is
145 molecular inversion probes (MIPs), which have now been used extensively to characterize drug
146 resistance and population structure in parasites in Africa.^{8,9,15} The ability to create and combine

147 different highly multiplexed panels for antimalarial resistance mutations, copy number variation,
148 gene deletions and other genome wide polymorphisms to study complexity of infection, parasite
149 relatedness or population structure makes the MIP platform a highly flexible and cost-effective
150 means of conducting malaria molecular surveillance (MMS).

151

152 The Molecular Surveillance of Malaria in Tanzania (MSMT) project was developed to provide
153 nationwide longitudinal surveillance of parasite populations to understand key aspects of parasite
154 biology that may impact malaria control and interventions.¹⁶ The emergence of 561H is a prime
155 concern for Tanzania given its proximity to Rwanda and previous studies documenting isolated
156 cases across the country, with two cases in the Chato district and one on the Eastern coast.^{9,17}
157 Here we describe the initial assessment of 6,278 successfully genotyped samples collected across
158 7,782 malaria positive individuals in the first year of the project using high-throughput MIP
159 analysis. The goal was to assess the status of antimalarial resistance in Tanzania, with a focus on
160 the border with Rwanda, to understand the distribution of the 561H mutation, partner drug
161 resistance and resistance to chemoprevention drugs. This was further supported by whole
162 genome sequencing of specific isolates to understand flanking haplotypes and gain insight into
163 the origins of 561H mutations in Tanzania.

164 MATERIALS AND METHODS

165 Study Design and Participants

166 We analyzed dried blood spot (DBS) samples from patients with a positive malaria rapid
167 diagnostic test drawn from cross-sectional surveys that involved 100 health facilities in 10
168 regions (n=7,148) and asymptomatic individuals in community studies (n=634) in three
169 additional regions (**Figure 1**). Details of the study sites' selection and overall sampling have
170 been provided elsewhere.¹⁶ The three community surveys were conducted in regions of Tanzania
171 which were involved in previous studies undertaken by the National Institute for Medical
172 Research (NIMR).^{9,18} Four regions (Kagera, Mara, Tabora, and Kigoma) were deemed high
173 priority areas for antimalarial resistance surveillance due to their proximity to Rwanda and to
174 their location in the Lake Zone of the country with higher transmission (**Figure 1**). Informed
175 consent was obtained for each patient and de-identified DBS samples were processed at NIMR in
176 Tanzania, Brown University, and University of North Carolina (USA) according to IRB
177 requirements of the Tanzanian Medical Research Coordinating Committee (MRCC) of NIMR.

178

179 Molecular Inversion Probe Analysis

180 DNA was extracted from the DBS using a Chelex-Tween protocol and MIP captures and
181 sequencing were conducted as previously described.¹⁵ This study used a panel specific for drug
182 resistance polymorphism detection and a panel to look at genomic diversity.¹⁵ Approximately
183 two to three thousand samples were run together on each NextSeq 500 run, and sample libraries
184 lacking sufficient read depth were rebalanced and resequenced. For samples from the high
185 priority regions (**Figure 1**), an additional MIP capture and high-depth sequencing was
186 conducted. Resulting data was analyzed using MIPTools software with freebayes variant
187 calling (<https://github.com/bailey-lab/MIPTools>).¹⁵ Controls for each MIP capture and
188 sequencing included DNA from 3D7 and 7G8 as well as no template and no probe controls.

189 Variant calling was conducted as previously described.¹⁵ We kept samples that had at least one
190 haplotype that mapped in the expected locations of the genome for any of our drug resistance
191 MIPs. Antimalarial resistance prevalence was calculated for all variants with a UMI count of 3 or
192 greater and if heterozygous with the alternate allele having 1 UMI or greater using a Python

193 script and maps were created using the `sf` package. Analysis of haplotypes involves only samples
194 where complete genotypes across the involved loci are available. Inheritance by descent (IBD)
195 analysis of parasite relatedness among ART-R parasitemias was done as previously described.⁸

196

197 **Whole Genome Sequencing**

198 Whole genome sequencing of selective whole genome amplification (sWGA) products was
199 attempted for 23 pure 561H, 5 mixed R561H, and 45 wildtype parasite infections based on MIP
200 genotyping. sWGA was performed in triplicate for each sample using a previously published
201 protocol and pooled.¹⁹ The pooled sWGA product was sheared using a LE220R-plus Covaris
202 Sonicator and libraries prepared using dual indexing with the Kappa Hyper Prep Kit (Roche,
203 Indianapolis, IN). Pooled libraries were sequenced on a NovaSeq6000 using 2 x 150 bp
204 chemistry at the University of North Carolina (UNC) High Throughput Sequencing Facility. We
205 also downloaded publicly available WGS data (n=25) from *P. falciparum* isolates collected in
206 2014/15 in Rwanda.¹⁰

207

208 Whole genome sequencing data was analyzed using GATK4 following previously published
209 methods (https://github.com/Karaniare/Optimized_GATK4_pipeline).²⁰ Briefly, reads were
210 mapped to the 3D7 reference genome using `bwa mem`, variants were called using GATK4 and
211 SNPs and indels were filtered using variant quality score recalibration. SNPs and indels passing
212 filters were visualized in R 4.2.1 using the `gt` package. In order to detect patterns of selection
213 signals between Southeast Asian (SEA), Rwanda and Tanzania haplotypes, we did extended-
214 haplotype homozygosity (EHH) statistics focusing 561H drug resistance SNP using filtered
215 biallelic SNPs and with low missingness data from a VCF file. All associated EHH calculations
216 were carried out using the R-package `rehh` (version 2.0.4). Rwanda and SEA data was
217 downloaded from Pf7K.

218 RESULTS

219 We successfully genotyped 6,278 of the 7,782 (80.7%) samples attempted (**Figure 1B**).
220 Sequencing across the K13 gene revealed three WHO validated ART-R mutations, 561H, 622I,
221 and 675V. The 561H mutations were predominantly found in Kagera, the northwest most region
222 bordering Rwanda and Uganda. (**Figure 2A, Table 1**). The overall prevalence in Kagera was
223 7.7% (50/649) and most of these mutant parasites were found in the west near the Rwandan
224 border in the districts of Karagwe at 22.8% (31/136), Kyerwa at 14.4% (17/118) and pfdhfr
225 and pfdhps mutations were common in the area studied (Table 2). Notably, we identified Ngara,
226 at 1.4% (2/144) (**Figure 2B**). Beyond Kagera, parasites with the 561H mutation were also
227 detected at lower prevalence in three other regions, including Tabora at 0.5% (2/438), Manyara
228 at 0.5% (1/179), and Njombe at 0.4% (1/279), as far as 800 km from the Rwanda border. The
229 K13 622I mutation was found in a single isolate from Njombe in Southwestern Tanzania (**Table**
230 **1**). The 675V mutation was found in one isolate from Kagera and one isolate from Tabora. Other
231 K13 propeller domain mutations not known to be associated with drug resistance were detected
232 sporadically (**Table S1**). Outside the K13 propeller domain, we found several polymorphisms
233 including 189T in 18.3% (397/2,168) of samples country-wide (**Table S1**). Other mutations have
234 putatively been associated with partial artemisinin resistance outside of K13, including
235 *Plasmodium falciparum* ATPase 6 (ATPase6) and *P. falciparum* AP-2mu (AP2mu) (**Table S1**).
236 The ATPase6 623E mutation was found in four Kagera isolates and seven Mara isolates (0.6%
237 and 2.3%, respectively), and none of these isolates contained parasites with mutations at K13
238 561H. *P. falciparum* coronin was not genotyped.

239

240 Extended haplotypes around antimalarial genes have been used to study the origin and spread of
241 mutations.¹⁰ With positive directional selection of resistance by drug pressure, large genomic
242 sections are spread in the population, a selective sweep, which are eventually broken down
243 through recombination. We achieved sufficient depth and quality on 29 of 63 Tanzanian isolates
244 from 2021 to assess the variation surrounding K13 and used publicly available WGS data from
245 the isolates collected in 2014/15 in Rwanda.¹⁰ We identify a shared haplotype between the older
246 Rwandan isolates and the contemporary Tanzanian isolates (n=4 from Tanzania; haplotype
247 RW/TZ1), suggesting cross-border spread resulting from a single origin event. However, a

248 second extended haplotype (n=5; TZ2) is also seen within the Tanzanian parasites (**Figure 3**).
249 RW/TZ1 and TZ2 differ at the closest flanking single nucleotide polymorphisms (within 1kb of
250 the 561H mutation). The TZ2 haplotype also does not appear to be of SEA origin (**Figure S1**).
251 Extended haplotype homozygosity analysis (EHH) shows extended haplotypes for RW/TZ1 and
252 TZ2 relative to wild type parasites, consistent with positive selection for both 561H haplotypes
253 (**Figure 4**). IBD analysis showed that 561H isolates from Kagera were closely related in multiple
254 small clusters (**Figure S2**). Of the more distant isolates, the two from Tabora were related to
255 Kagera isolates ($IBD \geq 0.25$), with the other two being more distant (**Figure S3**).

256

257 To investigate associations with mutations previously found to occur in drug resistant parasites
258 in Southeast Asia in combination with K13 mutations, we used the MIP panel genotypes and
259 quantified mutations occurring in the same isolates. None of *P. falciparum* chloroquine
260 resistance transporter (CRT) 326S, CRT 356T, *P. multidrug resistance protein 2* (MDR2) 484I,
261 *Plasmodium falciparum* Protein phosphatase (PPH) 1157L, or putative phosphoinositide-binding
262 protein (PIB7) 1484F were associated with K13 561H mutant isolates. However, ferredoxin (FD)
263 193Y polymorphisms were found in 13 K13 561H mutant isolates in Kagera (**Table S1**). Known
264 partner drug resistance mutations were also assessed (**Table 1**). In Kagera, 39 samples (39/586)
265 had mutations at CRT 76T, and 31 of these isolates were from Ngara bordering Rwanda and
266 Burundi (ASAQ is the most widely used ACT in Burundi). The multidrug resistance transporter
267 1 (MDR1) N86 allele associated with lumefantrine resistance was found in 99.9% of samples
268 (3828/3830). The MDR1 NFD haplotype (N86, 184F, D1246) was found in 52.6% of samples
269 (1420/2698).

270

271 Markers for SP resistance were also genotyped, revealing high frequency of many mutations and
272 the emergence of dihydrofolate reductase (DHFR) 164L in Kagera (**Table 1, Figure 2C**). The
273 folate synthesis gene triple mutations DHFR 51I, 59R and 108N were found to be near fixation
274 with the IRN haplotype at 92.5% (2,893/3,128). Notably, the DHFR 164L mutation was found at
275 15.2% (80/526) in Kagera region, accounting for 80% of the IRNL haplotypes found in the
276 country (100/2,524 nationally) (**Figure 2C**). In the dihydropteroate synthase (DHPS) gene, two
277 markers for elevated SP resistance were found to be above WHO guideline thresholds in some

278 regions. DHPS 540E was found at 93.06% (3,485/3,745) in Tanzania with little geographic
279 variation (**Table 1**), while DHPS 581G prevalence ranged from 0.4% (1/239) in Mtwara to
280 38.5% (25/65) in Tanga (**Figure 2D**).

281

282 DISCUSSION

283 Drug resistance in malaria parasites has emerged multiple times to every frontline antimalarial,
284 each time with severe consequences for affected populations.²¹ The emerging threat of ART-R in
285 Africa has the potential to be a global public health disaster. Thus, understanding the emergence
286 and spread of these mutations is critical in making plans to contain this threat. While it is clear
287 that K13 622I and 675V are spreading in the Horn of Africa and Uganda, respectively, the
288 pattern of origin and spread of the 561H mutation have not been fully defined. Here we
289 demonstrate that the mutation has risen to high frequencies in Kagera (7.7%), a region bordering
290 Rwanda, which had little evidence of resistance in a 2017 study that used MIPs to genotype
291 samples from Kagera in a national schoolkids survey (data not published). This trend would be
292 consistent with outward spread from the Rwanda-Tanzania border, and also supports the idea
293 that there has been and will continue to be regional spread of the mutation, especially given the
294 shared extended haplotype around some of the Tanzanian isolates and the older reported
295 Rwandan isolates. More concerning is the evidence of a potential unique origin of the 561H
296 mutation in the region, suggesting that ART-R may follow patterns similar to those seen in
297 Southeast Asia with multiple independent origins of the same mutation.²² Haplotype analysis
298 suggests multiple origins, but does not prove the mechanism behind them.⁶ If multiple origins
299 occur, containment efforts are more difficult, due to the need to closely monitor for new
300 haplotypes and the spread of specific haplotypes, which may not become extensive without
301 partner drug resistance. However, the presence of multiple haplotypes may be due to gene
302 conversion or recombination events adjacent to the mutation.

303

304 Several mutations in the K13 propeller domain that are now associated with delayed parasite
305 clearance are present in East Africa.⁶⁻⁸ The most concerning of these, 469Y, 561H, 622I and
306 675V, have shown clinical and *in vitro* validation of ART-R. Determining the exact origin of
307 these mutations with certainty is difficult due to the patchy nature of the surveillance data, but
308 one (561H) of the three appears to have originated on the Rwanda-Tanzania border. 561H was
309 first detected in Rwanda in 2015 as part of therapeutic efficacy studies and later in DRC and
310 Tanzania.^{9,10} To date, genotyping efforts to describe the status of K13 mutations in Tanzania
311 have been limited and do not capture the risk posed by ART-R parasites across the country. The

312 high rate of human movement across the border with Rwanda, where people have close historical
313 ties and One Stop Border Posts (OSPB) that routinely permit thousands of individuals and
314 hundreds of vehicles to cross daily, makes this a primary concern for malaria control in
315 Tanzania.²³ While there have been sporadic reports of validated ART-R polymorphisms in the
316 past, systematic longitudinal surveillance of these mutations is necessary to identify areas at risk,
317 as has been done in Uganda.^{6,9,17} The speed at which data is generated and reported to control
318 programs is critical. The MSMT project will provide these nationwide data for Tanzania given
319 the identified threat shown here of 561H in Kagera, by allowing yearly sampling and in-country
320 sequencing and analysis of data as the project develops.

321
322 Partner drug resistance surveillance showed important patterns. An intriguing pattern of CRT
323 76T mutations was found to be clustered near the Burundi border. A possible explanation is that
324 the use of ASAQ in Burundi is contributing to continued selection for chloroquine resistance and
325 that these resistant parasites are being imported into Kagera. Given artemether-lumefantrine
326 remains the first line antimalarial in Tanzania, it is not surprising that MDR1 N86 was near
327 fixation and the NFD haplotype was very common, occurring in over 50% of samples.

328
329 Markers of elevated SP resistance are increasing in Tanzania, which has potential impacts on the
330 use of SP as a chemopreventive antimalarial. The geographic distribution of the DHPS 581G
331 mutations in Tanzania has historically been limited to Tanga and the Lake districts.^{24,25} We
332 confirm that this remains the case with little evidence of expansion into other regions of
333 Tanzania. The reasons for the lack of spread of this mutation in Tanzania remains unclear and
334 warrants further evaluation, especially given the evidence that spread is occurring in the
335 neighboring Democratic Republic of the Congo.²⁶ Previous work has suggested that multiple
336 origins of parasites bearing 581G have occurred in East Africa, suggesting local origins and
337 limited spread.²⁷ However, that work was based on five microsatellites and may not take into
338 account the complex stepwise evolutionary history of mutations in DHPS. Importantly, a new
339 focus of the quadruple mutation in DHFR (51I, 59R, 108N, 164L) was identified in Kagera. In
340 the laboratory, this form of the enzyme binds pyrimethamine 600 times less tightly than the wild
341 type and about seven times less than the triple mutation (51I, 59R, 108N).²⁸ This results in

342 parasites being resistant to therapy *in vitro* at levels higher than what can be reached *in vivo*. The
343 DHFR/DHPS sextuple mutation (DHFR 51I, 59R, 108N / DHPS 437G, 540E, 581G), has been
344 associated with the compromise of intermittent preventive treatment in pregnancy (IPTp) and
345 was found in 11.2% (323/2,894) of samples nationally.²⁹ Given the regional high prevalence of
346 DHPS 581G and the emergence of DHFR 164L in Northwest Tanzania, additional studies are
347 warranted to evaluate the benefits of SP based chemoprevention in this region of Tanzania.

348

349 A major advantage of this study is the large geographic range and large number of samples
350 available for analysis. However, this study design also engenders some limitations. The large
351 number of samples resulted in overall low levels of coverage for the sequencing for most regions
352 (other than the four high priority regions that received extra depth). The samples collected at the
353 three cross-sectional sites performed poorly with our approach, likely due to low parasitemia.
354 The overall coverage in many regions may directly affect the ability to find minority drug
355 resistant variants in the data and we may have filtered out minor variants below 1%.


356

357 The detection of K13 561H at prevalence above 22% in Karagwe district of Kagera, Tanzania,
358 must raise alarms that ART-R is emerging and that ACTs efficacy is under threat. The
359 independent origin of a new K13 561H extended haplotype raises concern that multiple origins
360 of ART-R mutations will occur in Africa, complicating control. Evolution of partner drug
361 resistance must be monitored carefully and therapeutic efficacy studies are urgently needed to
362 understand the susceptibility of currently circulating K13 mutations in the region.

364 Table 1. Prevalence of antimalarial resistance mutations by region. Prevalence reflects the alternate allele.

Region	DHFR N51I	DHFR C59R	DHFR S108N	DHFR I164L	DHPS A437G	DHPS K540E	DHPS A581G	K13 A675V	K13 R561H	K13 R622I	MDR1 N86F	MDR1 N86Y	MDR1 Y184F	MDR1 D1246Y	CRT K76T
Kagera	0.987 (681/690)	0.913 (630/690)	1.0 (632/632)	0.1521 (80/526)	0.9408 (651/692)	0.9383 (654/697)	0.2593 (189/729)	0.0015 (1/680)	0.077 (50/649)	0.0 (0/709)	0.0 (0/223)	0.0 (0/223)	0.4936 (115/233)	0.0087 (1/115)	0.0164 (2/122)
Mara	0.988 (574/581)	0.926 (538/581)	0.9947 (563/566)	0.0305 (17/558)	0.9701 (551/568)	0.9724 (563/579)	0.0085 (5/590)	0.0 (0/585)	0.0 (0/535)	0.0 (0/578)	0.0 (0/75)	0.0 (0/75)	0.337 (31/92)	0.0404 (4/99)	0.1395 (12/86)
Dodoma	0.9787 (184/188)	0.9149 (172/188)	1.0 (145/145)	0.01 (1/100)	0.9509 (155/163)	0.9369 (193/206)	0.0543 (12/221)	0.0 (0/182)	0.0 (0/158)	0.0 (0/188)	0.0 (0/521)	0.0019 (1/521)	0.5204 (280/538)	0.0511 (21/411)	0.0052 (2/381)
Ruvuma	1.0 (65/65)	0.9846 (64/65)	1.0 (60/60)	0.0 (0/46)	0.9444 (51/54)	0.9275 (64/69)	0.0278 (2/72)	0.0 (0/68)	0.0 (0/38)	0.0 (0/68)	0.0 (0/60)	0.0 (0/60)	0.3623 (25/69)	0.0571 (2/35)	0.0 (0/50)
Manyara	0.9908 (216/218)	0.9679 (211/218)	1.0 (162/162)	0.011 (1/91)	0.9235 (169/183)	0.9174 (200/218)	0.2273 (55/242)	0.0 (0/202)	0.0056 (1/179)	0.0 (0/202)	0.0 (0/236)	0.0 (0/236)	0.5679 (138/243)	0.0171 (2/117)	0.0078 (1/128)
Songwe	0.9945 (360/362)	0.9613 (348/362)	1.0 (328/328)	0.0044 (1/228)	0.9254 (310/335)	0.9218 (342/371)	0.0201 (8/399)	0.0 (0/362)	0.0 (0/346)	0.0 (0/377)	0.0 (0/377)	0.0 (0/377)	0.4197 (162/386)	0.0034 (1/293)	0.0 (0/270)
Tanga	1.0 (58/58)	0.9483 (55/58)	1.0 (49/49)	0.0 (0/48)	0.9184 (45/49)	0.8571 (54/63)	0.3846 (25/65)	0.0 (0/56)	0.0 (0/30)	0.0 (0/45)	0.0058 (2/342)	0.0058 (2/342)	0.5141 (182/354)	0.0036 (1/277)	0.035 (10/286)
Tabora	0.9902 (504/509)	0.943 (480/509)	0.9977 (436/437)	0.016 (6/376)	0.9725 (459/472)	0.975 (506/519)	0.036 (20/555)	0.0022 (1/464)	0.0046 (2/438)	0.0 (0/498)	0.0 (0/213)	0.0047 (1/213)	0.6197 (132/213)	0.0181 (3/166)	0.0331 (6/181)
Kigoma	1.0 (94/94)	0.9149 (86/94)	1.0 (88/88)	0.0 (0/88)	1.0 (92/92)	1.0 (87/87)	0.3232 (32/99)	0.0 (0/100)	0.0 (0/73)	0.0 (0/94)	0.0 (0/215)	0.0 (0/215)	0.5411 (125/231)	0.0 (0/70)	0.0 (0/63)
Kilimanjaro	0.9951 (202/203)	0.9557 (194/203)	1.0 (185/185)	0.0 (0/173)	0.9524 (180/189)	0.9608 (196/204)	0.3594 (78/217)	0.0 (0/204)	0.0 (0/172)	0.0 (0/198)	0.0 (0/556)	0.0018 (1/556)	0.637 (372/584)	0.0271 (15/554)	0.0054 (3/555)
Njombe	0.991 (329/332)	0.9548 (317/332)	1.0 (291/291)	0.0 (0/246)	0.9121 (280/307)	0.8991 (303/337)	0.0474 (17/359)	0.0 (0/331)	0.0036 (1/279)	0.0029 (1/345)	0.0 (0/238)	0.0 (0/238)	0.5754 (145/252)	0.0109 (1/92)	0.0 (0/97)
Mtwara	0.8602 (160/186)	0.9462 (176/186)	1.0 (107/107)	0.0 (0/77)	0.8025 (126/157)	0.7857 (165/210)	0.0042 (1/239)	0.0 (0/170)	0.0 (0/137)	0.0 (0/144)	0.0014 (1/711)	0.0042 (3/711)	0.4446 (325/731)	0.0295 (18/610)	0.0666 (39/586)
Dar es Salaam	0.9548 (169/177)	0.9266 (164/177)	0.9914 (115/116)	0.0 (0/49)	0.8286 (116/140)	0.8541 (158/185)	0.1198 (26/217)	0.0 (0/161)	0.0 (0/137)	0.0 (0/135)	0.0 (0/63)	0.0 (0/63)	0.5385 (42/78)	0.0 (0/41)	0.0 (0/56)
Overall	0.9817 (3596/3663)	0.9378 (3435/3663)	0.9984 (3161/3166)	0.0407 (106/2606)	0.9365 (3185/3401)	0.9306 (3485/3745)	0.1174 (470/4004)	0.0006 (2/3565)	0.017 (54/3171)	0.0003 (1/3581)	0.0008 (3/3830)	0.0021 (8/3830)	0.518 (2074/4004)	0.024 (69/2880)	0.0262 (75/2861)

365 **FIGURES**




366

367 **Figure 1. Tanzania malaria prevalence and study design.** Panel A depicts a map of Tanzania
368 showing malaria prevalence in children aged 0-59 months in 2017 as a color gradient (National
369 Malaria Control Program data). Health facilities where sampling occurred for this study are
370 shown as green dots, while community cross sectional collection sites are shown as yellow
371 squares. Panel B shows the study design flowchart showing the number of samples collected at
372 health facilities and cross sectional surveys and the success of genotyping. Priority for
373 genotyping and analysis was given to regions in the northwest.

374

375




376

377 **Figure 2. Antimalarial resistance polymorphisms in Tanzania.** Panels A and B show K13
378 561H mutations in Tanzania by region (A) and by district in Kagera (B). In Panel A, white areas
379 represent no sampling, gray areas represent sampled areas where no K13 561H was found, and
380 colored areas are shaded by the frequency of samples with the 56H mutation. The red box
381 surrounds the area plotted in Panel B, which is a map of Kagera showing K13 561H prevalence
382 in each district sampled. DHFR 164L (Panel C) and DHPS 581G (Panel D) prevalence in
383 sampled regions are shown in color gradients. Regions with no sampling are shown in white and
384 regions where a polymorphism was not detected is shown in grey.

385


386



387

388 **Figure 3. Extended flanking haplotype plot around K13 561H mutations.** Pure mutant 561H
389 are shown in maroon. Rwandan isolates are in the blue box, while Tanzanian isolates are shown
390 in the red boxes. Grey regions represent loci where a call could not be made.

391



392

393 **Figure 4. Extended Haplotype Heterozygosity (EHH) analysis of 561H haplotypes.** Panel A
394 shows the extended haplotype for the RW/TZ1 561H haplotype (red-derived) compared to
395 wildtype parasites (blue-ancestral). Panel B shows the extended haplotype of the TZ2 561H
396 haplotype.

397

398 **Authors contribution**

399 DSI, JJJ and JB formulated the original idea. DSI, CIM, RAM, MDS and CB conducted the field
400 surveys. DG, AF, AS, BL, ZPH, KN and AL performed data analysis under the guidance of
401 DSI, JJJ and JB. JJJ, AS, AF, DG, BL, ZPH, CB, DP, MDS, JB, and DSI wrote and edited the
402 manuscript. All authors contributed to the article and approved the submitted version.

403 **Acknowledgements:**

404 The authors wish to thank participants and parents/guardians of all children who took part in the
405 surveillance. We acknowledge the contribution of the following project staff and other
406 colleagues who participated in data collection and/or laboratory processing of samples; Raymond
407 Kitengeso, Ezekiel Malecela, Muhidin Kassim, Athanas Mhina, August Nyaki, Juma Tupa,
408 Anangisye Malabeja, Emmanuel Kessy, George Gesase, Tumaini Kamna, Grace Kanyankole,
409 Oswald Osca, Richard Makono, Ildephonc Mathias, Godbless Msaki, Rashid Mtumba, Gasper
410 Lugela, Gineson Nkya, Daniel Chale, Richard Malisa, Sawaya Msangi, Ally Idrisa, Francis
411 Chambo, Kusa Mchaina, Raymond Kitengeso, Neema Barua, Christian Msokame, Rogers
412 Msangi, Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusu, Jumaa Akida,
413 Ambele Yatinga, Tilaus Gustav, Oksana Kharabora and Claudia Gaither. The finance,
414 administrative and logistic support team at NIMR: Christopher Masaka, Millen Meena, Beatrice
415 Mwampeta, Gracia Sanga, Neema Manumbu, Halfan Mwanga, Arison Ekoni, Twalipo Mponzi,
416 Pendael Nasary, Denis Byakuzana, Alfred Sezary, Emmanuel Mnzava, John Samwel, Daud
417 Mjema, Seth Nguhu, Thomas Semdoe, Sadiki Yusuph, Alex Mwakibinga, Rodrick Ulomi and
418 Andrea Kimboi. Management of the National Institute for Medical Research, National Malaria
419 Control Program and President's Office-Regional Administration and Local Government
420 (Regional administrative secretaries of the 13 regions, and district officials, staff from all 100
421 HFs and Community Health Workers from the 3 community cross sectional regions. Technical
422 and logistics support from the Bill and Melinda Gates Foundation team is highly
423 appreciated. Permission to publish the manuscript was sought and obtained from the Director
424 General of NIMR.

425 **Funding**

426 This work was supported, in whole, by the Bill & Melinda Gates Foundation [grant number
427 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0
428 Generic License has already been assigned to the Author Accepted Manuscript version that
429 might arise from this submission. This study was also funded by the National Institute for
430 Allergy and Infectious Diseases (R01AI156267 to JAB, DSI and JJJ; K24AI134990 to JJJ).

431 **Data Availability:** All sequencing data has been submitted to SRA (# pending). Other metadata
432 is available from the corresponding author upon reasonable request. Code for analysis is
433 available at: https://github.com/bailey-lab/MSMT_2021_DR_analyses.

434 **REFERENCES**

- 435 1 World Health Organization. World malaria report 2022. World Health Organization, 2022.
- 436 2 Trape JF. The public health impact of chloroquine resistance in Africa. *Am J Trop Med Hyg*
437 2001; **64**: 12–7.
- 438 3 Spring MD, Lin JT, Manning JE, *et al.* Dihydroartemisinin-piperazine failure associated
439 with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
440 *Lancet Infect Dis* 2015; **15**: 683–91.
- 441 4 Programme GM. Report on antimalarial drug efficacy, resistance and response: 10 years of
442 surveillance (2010-2019). 2020; published online Nov 19.
443 <https://www.who.int/publications/i/item/9789240012813> (accessed Oct 30, 2023).
- 444 5 Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-
445 based combination therapies. *Curr Opin Microbiol* 2022; **69**: 102193.
- 446 6 Conrad MD, Asua V, Garg S, *et al.* Evolution of Partial Resistance to Artemisinins in
447 Malaria Parasites in Uganda. *N Engl J Med* 2023; **389**: 722–32.
- 448 7 Mihreteab S, Platon L, Berhane A, *et al.* Increasing Prevalence of Artemisinin-Resistant
449 HRP2-Negative Malaria in Eritrea. *N Engl J Med* 2023; **389**: 1191–202.
- 450 8 Fola AA, Feleke SM, Mohammed H, *et al.* Plasmodium falciparum resistant to artemisinin
451 and diagnostics have emerged in Ethiopia. *Nat Microbiol* 2023; **8**: 1911–9.
- 452 9 Moser KA, Madebe RA, Aydemir O, *et al.* Describing the current status of Plasmodium
453 falciparum population structure and drug resistance within mainland Tanzania using
454 molecular inversion probes. *Mol Ecol* 2020; published online Oct 26.
455 DOI:10.1111/mec.15706.
- 456 10 Uwimana A, Legrand E, Stokes BH, *et al.* Emergence and clonal expansion of in vitro
457 artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.
458 *Nat Med* 2020; published online Aug 3. DOI:10.1038/s41591-020-1005-2.
- 459 11 Bayih AG, Getnet G, Alemu A, Getie S, Mohon AN, Pillai DR. A Unique Plasmodium
460 falciparum K13 Gene Mutation in Northwest Ethiopia. *Am J Trop Med Hyg* 2016; **94**: 132–
461 5.
- 462 12 Kirby R, Giesbrecht D, Karema C, *et al.* Examining the Early Distribution of the
463 Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher
464 Transmission in Rwanda. *Open Forum Infect Dis* 2023; **10**: ofad149.
- 465 13 Uwimana A, Umulisa N, Venkatesan M, *et al.* Association of Plasmodium falciparum
466 kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label,
467 single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis* 2021; **21**: 1120–8.

- 468 14 WHO | Status report on artemisinin and ACT resistance (April 2017). World Health
469 Organization, 2017 [https://www.who.int/malaria/publications/atoz/artemisinin-resistance-](https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/)
470 [april2017/en/](https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/) (accessed Feb 3, 2020).
- 471 15 Verity R, Aydemir O, Brazeau NF, *et al.* The impact of antimalarial resistance on the
472 genetic structure of *Plasmodium falciparum* in the DRC. *Nat Commun* 2020; **11**: 2107.
- 473 16 Rogier E, Battle N, Bakari C, *et al.* *Plasmodium falciparum* p_{fh}rp2 and p_{fh}rp3 gene
474 deletions among patients enrolled at 100 health facilities throughout Tanzania: February to
475 July 2021. bioRxiv. 2023; published online Aug 5. DOI:10.1101/2023.07.29.23293322.
- 476 17 Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of
477 mutations associated with artemisinin resistance at k13-propeller gene and a near complete
478 return of chloroquine susceptible *falciparum* malaria in Southeast of Tanzania. *Sci Rep*
479 2020; **10**: 1–7.
- 480 18 Ishengoma DS, Mmbando BP, Mandara CI, *et al.* Trends of *Plasmodium falciparum*
481 prevalence in two communities of Muheza district North-eastern Tanzania: correlation
482 between parasite prevalence, malaria interventions and rainfall in the context of re-
483 emergence of malaria after two decades of progressively declining transmission. *Malar J*
484 2018; **17**: 252.
- 485 19 Oyola SO, Ariani CV, Hamilton WL, *et al.* Whole genome sequencing of *Plasmodium*
486 *falciparum* from dried blood spots using selective whole genome amplification. *Malar J*
487 2016; **15**. DOI:10.1186/s12936-016-1641-7.
- 488 20 Niaré K, Greenhouse B, Bailey JA. An optimized GATK4 pipeline for *Plasmodium*
489 *falciparum* whole genome sequencing variant calling and analysis. *Malar J* 2023; **22**: 207.
- 490 21 Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking *Plasmodium*
491 *falciparum* parasite biology to the clinic. *Nat Med* 2017; **23**: 917–28.
- 492 22 Takala-Harrison S, Jacob CG, Arze C, *et al.* Independent emergence of artemisinin
493 resistance mutations among *Plasmodium falciparum* in Southeast Asia. *J Infect Dis* 2015;
494 **211**: 670–9.
- 495 23 Katalyeba PO. Rural - Rural Movements in East Africa: a Study of Rwandan and Southern
496 Ugandans in Karagwe District, Tanzania. 2002.
497 <http://researcharchive.vuw.ac.nz/handle/10063/461> (accessed Oct 28, 2023).
- 498 24 Gesase S, Gosling RD, Hashim R, *et al.* High resistance of *Plasmodium falciparum* to
499 sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance
500 mutation at Codon 581. *PLoS One* 2009; **4**: e4569.
- 501 25 Ngondi JM, Ishengoma DS, Doctor SM, *et al.* Surveillance for sulfadoxine-pyrimethamine
502 resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling and
503 next-generation sequencing. *Malar J* 2017; **16**: 236.

- 504 26 Deutsch-Feldman M, Aydemir O, Carrel M, *et al.* The changing landscape of Plasmodium
505 falciparum drug resistance in the Democratic Republic of Congo. *BMC Infect Dis* 2019; **19**:
506 872.
- 507 27 Taylor SM, Antonia AL, Harrington WE, *et al.* Independent lineages of highly sulfadoxine-
508 resistant Plasmodium falciparum haplotypes, eastern Africa. *Emerg Infect Dis* 2014; **20**:
509 1140–8.
- 510 28 Hyde JE. Antifolate resistance in Africa and the 164-dollar question. *Trans R Soc Trop Med*
511 *Hyg* 2008; **102**. DOI:10.1016/j.trstmh.2008.01.003.
- 512 29 Chico RM, Cano J, Ariti C, *et al.* Influence of malaria transmission intensity and the 581G
513 mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic
514 review and meta-analysis. *Trop Med Int Health* 2015; **20**: 1621–33.

515